These carryover should not result in the carryover of degradants or microbial contamination that will adversely change the founded API impurity profile.(biotech) refers back to the utilization of cells or organisms that have been produced or modified by recombinant DNA, hybridoma, or other technologies to provide APIs. The APIs made by biotechnolog